Neurofibromatosis Type 1

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status.

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors

Interventions for Reading Disabilities in NF1

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas

A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1

A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours

International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia

A Study of Selumetinib in Patients With Kaposi's Sarcoma

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Selumetinib Paediatric NF1 Japan Study

Selumetinib and Olaparib in Solid Tumors

Intermittent Selumetinib for Uveal Melanoma

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy Subjects

To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects

To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers

Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer

ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer

An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1

Real-World Treatment Study of Koselugo (Selumetinib)

Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia

PASS of Paediatric Patients Initiating Selumetinib

US Selumetinib Registry

Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1

Adaptation and Quality of Life Among Adults With Neurofibromatosis Type I